Boehringer Ingelheim (OTC: BIIBF) Advances Lung Cancer Treatment Research
Key Developments Boehringer Ingelheim (OTC: BIIBF) has announced a new clinical exploration combining a DLL3-targeting T-cell engager with a PD-L1/VEGF-A bispecific antibody to treat small cell lung cancer (SCLC). This innovative approach aims to simultaneously stimulate immune attack on tumor cells and modulate the tumor microenvironment for improved patient outcomes. The company is initiating this combination to evaluate synergistic effects on tumor suppression and immune system activation, reflecting Boehringer Ingelheim’s…
